• Research Tree
  • Features
  • Pricing
  • Events
  • Reg.News
  • Short Interest
  • Explore Content
    • Explore

      • Providers
        • Providers

          • Free/Commissioned
          • High Net Worth Offering
          • Institutional Offering

          Free/Commissioned

          Research that is free to access for all investors. Companies commission these providers to write research about them.

          View Research

          What is our Main Bundle Offering?

          Brokers who write research on their corporate clients and make it available through our main bundle offering.

          View Research

          What is Institutional?

          Research that is paid for directly by asset managers. Only accessible to institutional investors permissioned for access.

          View Research
      • Regions
        • Regions

          • UK
          • Rest of EMEA
          • N America
          • APAC
          • LatAm
      • Exchanges
        • Exchanges

          • Aquis Apex
          • Australian Securities Exchange
          • Canadian Securities Exchange
          • Euronext Paris
          • London Stock Exchange (domestic)
          • SIX Swiss Exchange
      • Sectors
        • Sector Coverage

          • Building & Construction
          • Discretionary Personal Goods
          • Discretionary Retail
          • Energy
          • Health
          • Investment Trusts
          • Media
          • Resources
          • Technology
      • Small / Large Cap
        • Small / Large Cap

          • UK100
          • UK250
          • UK Smallcap
          • UK Other Main Markets
          • Other
  • Login
  • Sign Up
LIVE

Event in Progress:

Join Here ×

working
  • 20 Feb 2026

2025 Was A Foundational Year, In Our View; Lower Near-Term Estimates On Soft Demand; Free Cash Flow And Deleveraging Reinforce Our 2027 Earnings Framework; Maintain $21 Price Target


Schweitzer-Mauduit International (SWM:NYSE) | 0 0 0.0%


  • Sidoti & Company
    • Daniel Harriman

    • 10 pages


 

MATV reported 4Q:25 sales of $463.1 million, adjusted EPS of $0.15 and adjusted free cash flow (FCF) of $5.5 million. Results compared favorably to our estimates of $461.1 million in sales, $0.09 in adjusted EPS and an adjusted FCF outflow of $5.8 million. Organic sales increased nearly 2% year over year in 4Q:25, reflecting favorable currency and higher selling prices, partially offset by lower volume and mix in certain end markets. Filtration & Advanced Materials (FAM) marked its second quarter of annual sales growth since the merger, with revenue increasing more than 5% year over year, supported by improved volume and mix and favorable currency translation. Sustainable & Adhesive Solutions (SAS) organic sales were largely flat year over year on an organic basis, as favorable currency and pricing were offset by lower volumes in labels, automotive tapes and release liners, particularly in Europe. Full-year 2025 FCF of $94 million marked the highest level since the merger and more than doubled the prior year, enabling $61 million of net debt reduction and year-end net leverage of 4.2x. We are lowering our 2026 estimates to reflect continued anemic demand and muted volume growth. We now model 2026 sales of $2.015 billion (from $2.050 billion), adjusted EPS of $0.85 (from $1.00) and adjusted free cash flow of $80 million (from $100 million). We maintain our 2027 estimates of $2.150 billion in sales, $1.25 in adjusted EPS and $125 million in adjusted free cash flow, reflecting expected operating leverage once volumes normalize. We maintain our $21 price target on MATV shares, which remains based on a 17x multiple to our 2027 adjusted EPS estimate of $1.25. New leadership, combined with the company's portfolio transformation and focus on the higher-growth platforms of its business, support our moderate risk rating.

Sign up for free to access

Get access to the latest equity research in real-time from 12 commissioned providers.

Get access to the latest equity research in real-time from 12 commissioned providers.


Get Started
Already a member? Log in here
See all the research we have on this company.

2025 Was A Foundational Year, In Our View; Lower Near-Term Estimates On Soft Demand; Free Cash Flow And Deleveraging Reinforce Our 2027 Earnings Framework; Maintain $21 Price Target


Schweitzer-Mauduit International (SWM:NYSE) | 0 0 0.0%


  • Published: 20 Feb 2026
  • Author: Daniel Harriman
  • Pages: 10
  • Sidoti & Company


MATV reported 4Q:25 sales of $463.1 million, adjusted EPS of $0.15 and adjusted free cash flow (FCF) of $5.5 million. Results compared favorably to our estimates of $461.1 million in sales, $0.09 in adjusted EPS and an adjusted FCF outflow of $5.8 million. Organic sales increased nearly 2% year over year in 4Q:25, reflecting favorable currency and higher selling prices, partially offset by lower volume and mix in certain end markets. Filtration & Advanced Materials (FAM) marked its second quarter of annual sales growth since the merger, with revenue increasing more than 5% year over year, supported by improved volume and mix and favorable currency translation. Sustainable & Adhesive Solutions (SAS) organic sales were largely flat year over year on an organic basis, as favorable currency and pricing were offset by lower volumes in labels, automotive tapes and release liners, particularly in Europe. Full-year 2025 FCF of $94 million marked the highest level since the merger and more than doubled the prior year, enabling $61 million of net debt reduction and year-end net leverage of 4.2x. We are lowering our 2026 estimates to reflect continued anemic demand and muted volume growth. We now model 2026 sales of $2.015 billion (from $2.050 billion), adjusted EPS of $0.85 (from $1.00) and adjusted free cash flow of $80 million (from $100 million). We maintain our 2027 estimates of $2.150 billion in sales, $1.25 in adjusted EPS and $125 million in adjusted free cash flow, reflecting expected operating leverage once volumes normalize. We maintain our $21 price target on MATV shares, which remains based on a 17x multiple to our 2027 adjusted EPS estimate of $1.25. New leadership, combined with the company's portfolio transformation and focus on the higher-growth platforms of its business, support our moderate risk rating.

More Content

More Content

In Our View, 4Q:25 Seasonal Moderation Masks Structural Progress As Execution, Portfolio Discipline, And Deleveraging Continue; Maintain $21 Price Target

Companies: Schweitzer-Mauduit International

Sidoti & Company

Expect Sequential Improvement As SAS Delivers And FAM Stabilizes; Maintain 2025/26 Estimates As New Leadership Drives Early Execution Amid An Uneven Recovery; Maintain $16 Price Target

Companies: Schweitzer-Mauduit International

Sidoti & Company

2026 Preview: Cost Actions, Portfolio Focus, And Segment Stabilization Position MATV For Better Performance In First Full Year Under New Leadership; Maintain $21 Price Target

Companies: Schweitzer-Mauduit International

Sidoti & Company

Strong 2Q:25 Results Highlight Progress Of Turnaround; Cost Discipline, Commercial Execution, And FCF Momentum Support 2026 Estimate Revisions; Raise Price Target to $19 (From $16)

Companies: Schweitzer-Mauduit International

Sidoti & Company

MATV's Swift Recovery Gains Momentum Despite Market Uncertainty; Record Margins And Strong Cash Generation Underscore Good Execution, In Our View; Raise Price Target To $21 (From $19)

Companies: Schweitzer-Mauduit International

Sidoti & Company
Research Tree
Useful Links
  • Features
  • Pricing
  • RNS/Newswires Feeds
  • Providers Hub
  • Company Hub
  • Stock Pick League
  • iOS and Android Apps
Account
  • Login
  • Join Now
  • Contact
  • Follow us on Linkedin
  • Follow us on X

© Research Tree 2026

  • Apple Store
  • Play Store
  • Terms of Service
  • Privacy Policy and Statement on Cookies

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Top
  • Home
  • Features
  • Pricing
  • Event Hub
  • Reg.News
  • Short Interest Tracker
  • Explore Content
    • Regions
      • UK
      • Rest of EMEA
      • N America
      • APAC
      • LatAm
    • Exchanges
      • Aquis Apex
      • Australian Securities Exchange
      • Canadian Securities Exchange
      • Euronext Paris
      • London Stock Exchange (domestic)
      • SIX Swiss Exchange
    • Sectors
      • Automobile Industry
      • Banks
      • Building & Construction
      • Chemicals
      • Discretionary Personal Goods
      • Discretionary Retail
      • Energy
      • ETFs
      • Financial Services
      • Food & Drink
      • Food Production
      • Health
      • Household Goods & DIY
      • Industrial Equipment, Goods & Services
      • Insurance & Reinsurance
      • Investment Trusts
      • Leisure, Tourism & Travel
      • Media
      • Open-ended Funds
      • Other
      • Real Estate
      • Resources
      • Staple Retail
      • Technology
      • Telecoms
      • Trusts, ETFs & Funds
      • Utilities
    • Small / Large Cap
      • UK100
      • UK250
      • UK Smallcap
      • UK Other Main Markets
      • Other
    • Private/EIS
      • EIS Single Company
      • EIS/SEIS Funds
      • IHT Products
      • SEIS Single Company
      • VCT Funds
  • Providers
    • Free/Commissioned
      • Actinver
      • Actio Advisors
      • Allenby Capital
      • Alternative Resource Capital
      • Asset TV
      • Astris Advisory
      • Atrium Research
      • Baden Hill
      • BlytheRay
      • BNP Paribas Exane - Sponsored Research
      • Bondcritic
      • Bowsprit Partners Limited
      • Brand Communications
      • Brokerlink
      • BRR Media
      • Calvine Partners
      • Capital Access Group
      • Capital Link
      • Capital Markets Brokers
      • Cavendish
      • Checkpoint Partners
      • Clear Capital Markets
      • Couloir Capital
      • Doceo
      • Edison
      • EM Spreads
      • Engage Investor
      • Equity Development
      • eResearch
      • First Equity
      • Five Minute Pitch TV
      • focusIR
      • Fundamental Research Corp
      • Galliano’s Latin Notes
      • GBC AG
      • goetzpartners securities Limited
      • Golden Section Capital
      • GreenSome Finance
      • GSBR Research
      • H2 Radnor
      • Hardman & Co
      • Holland Advisors
      • Hypothesis Research
      • InterAxS Global
      • Kepler | Trust Intelligence
      • London Stock Exchange
      • Longspur Clean Energy
      • Mello Events
      • Messari Research
      • Morphose Capital Partners
      • MUFG Corporate Markets IR
      • Nippon Investment Bespoke Research UK
      • NuWays
      • OAK Securities
      • Oberon Capital
      • Optimo Capital
      • Panmure Liberum
      • Paul Scott
      • Peel Hunt
      • PIWORLD / Progressive
      • Proactive
      • Progressive Equity Research
      • Quantum Research Group
      • QuotedData
      • RaaS Research Group
      • Research Dynamics
      • Research Tree
      • Resolve Research
      • SEAL Advisors Ltd
      • ShareSoc
      • Shore Capital
      • Sidoti & Company
      • Small Cap Consumer Research LLC
      • StockBox
      • Tennyson Securities
      • The AIC
      • The Business Magazine Group
      • The Curious Compounder
      • The Edge Group
      • The Life Sciences Division
      • ThinkFront
      • Tring Triangle
      • Trinity Delta
      • Turner Pope Investments
      • UK Investor Group
      • ValueTrack
      • Vox Markets
      • VRS International S.A. - Valuation & Research Specialists (VRS)
      • VSA Capital
      • Winterflood Securities
      • World Platinum Investment Council
      • Yaru Investments
      • Yellowstone Advisory
      • Zacks Small Cap Research
      • Zeus Capital
    • High Net Worth Offering
      • ABG Sundal Collier
      • ACF Equity Research
      • Acquisdata
      • AlphaValue
      • Arctic Securities
      • Arden Partners
      • Auctus Advisors
      • Baptista Research
      • BNP Paribas Exane - Sponsored Research
      • Canaccord Genuity
      • Cavendish
      • Couloir Capital
      • Degroof Petercam
      • Dowgate Capital
      • First Berlin
      • First Equity
      • First Sentinel
      • Greenwood Capital Partners
      • Hannam & Partners
      • Hybridan
      • ISTAR Capital
      • Kemeny Capital
      • Longspur Clean Energy
      • Louis Capital
      • Magnitogorsk Iron and steel works
      • Medley Global Advisors
      • Northland Capital Partners
      • OAK Securities
      • Oberon Capital
      • Panmure Liberum
      • QuotedData Professional
      • Shard Capital
      • ShareSoc
      • Shore Capital
      • Singer Capital Markets
      • SP Angel
      • Stanford Capital Partners
      • Stifel FirstEnergy
      • Stockdale Securities
      • Tamesis Partners
      • Tennyson Securities
      • The Life Sciences Division
      • Turner Pope Investments
      • VSA Capital
      • Whitman Howard
      • xxxxxx_deleted
      • Yellowstone Advisory
      • Zeus Capital
    • Institutional Offering
      • ABG Sundal Collier
      • ACF Equity Research
      • Alternative Resource Capital
      • Arctic Securities
      • Arden Partners
      • Auctus Advisors
      • BNP Paribas Exane
      • Bondcritic
      • Canaccord Genuity
      • Capital Access Group
      • Capital Link
      • Cavendish
      • Couloir Capital
      • Degroof Petercam
      • Dowgate Capital
      • Edison
      • First Berlin
      • First Equity
      • First Sentinel
      • Five Minute Pitch TV
      • Fundamental Research Corp
      • Galliano’s Latin Notes
      • GBC AG
      • Golden Section Capital
      • Goodbody
      • Greenwood Capital Partners
      • Hannam & Partners
      • Holland Advisors
      • Hybridan
      • InterAxS Global
      • Investec Bank
      • ISTAR Capital
      • Kepler | Trust Intelligence
      • Longspur Clean Energy
      • Numis
      • NuWays
      • OAK Securities
      • Oberon Capital
      • Panmure Liberum
      • Peel Hunt
      • QuotedData
      • QuotedData Professional
      • Research Dynamics
      • Research Tree
      • Shard Capital
      • Shore Capital
      • Sidoti & Company
      • Singer Capital Markets
      • Small Cap Consumer Research LLC
      • SP Angel
      • Stanford Capital Partners
      • Stifel
      • StockBox
      • Tamesis Partners
      • Tennyson Securities
      • The AIC
      • The Business Magazine Group
      • The Life Sciences Division
      • Tring Triangle
      • ValueTrack
      • Velocity Trade
      • VSA Capital
      • Winterflood Securities
      • World Platinum Investment Council
      • Zacks Small Cap Research
      • Zeus Capital
  • Contact
  • Sign Up
  • Sign In